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Impairment of microglial functions, such as phagocytosis and/
or dysregulation of immune responses, has been implicated
as an underlying factor involved in the pathogenesis of
various neurodegenerative disorders. Our previous studies
have demonstrated that long intergenic noncoding RNA
(lincRNA)-Cox2 expression is influenced by nuclear factor
kB (NF-kB) signaling and serves as a coactivator of transcrip-
tional factors to regulate the expression of a vast array of im-
mune-related genes in microglia. Extracellular vesicles (EVs)
have been recognized as primary facilitators of cell-to-cell
communication and cellular regulation. Herein, we show that
EVs derived from astrocytes exposed to morphine can be taken
up by microglial endosomes, leading, in turn, to activation of
Toll-like receptor 7 (TLR7) with a subsequent upregulation
of lincRNA-Cox2 expression, ultimately resulting in impaired
microglial phagocytosis. This was further validated in vivo,
wherein inhibition of microglial phagocytic activity was also
observed in brain slices isolated from morphine-administrated
mice compared with control mice. Additionally, we also
showed that intranasal delivery of EVs containing lincRNA-
Cox2 siRNA (small interfering RNA) was able to restore micro-
glial phagocytic activity in mice administered morphine. These
findings have ramifications for the development of EV-loaded
RNA-based therapeutics for the treatment of various disorders
involving functional impairment of microglia.
INTRODUCTION
Opioid analgesics, of which morphine is a classic example, are used
extensively in the clinical setting for pain management owing to their
beneficial effects. Paradoxically, however, there are also deleterious
side effects associated with opiates such as opioid tolerance, addiction,
and decline in cognitive performance.1,2 Opiates exert dramatic ef-
fects on phagocytic cells including microglia, the resident phagocytic
cells of the brain.3–5 Rapid phagocytic removal of dead, dying, in-
fected cells or microbes is vital for brain homeostasis and for proper
resolution of the insult by removing immunogens and limiting exces-
sive immune responses.6 Phagocytic cells via their cell surface recep-
tors can recognize pathogenic microorganisms and cellular debris
that, in turn, trigger the internal cellular machinery resulting in the
ingestion of the particles into the phagosomes, which can fuse with
the lysosomes to be ultimately degraded in the phagolysosomes.7,8
It has been well documented that the “find-me” and “eat-me” signals
released by apoptotic cells serve to attract the phagocytes, resulting in
the engulfment and clearance of apoptotic cells to maintain tissue ho-
meostasis.9,10 In the CNS, impairment of microglial phagocytosis ren-
ders the microglia unable to engulf and eliminate toxic pathogens and
cellular debris, ultimately culminating in a toxic inflammatory milieu,
a common feature underlying various neurodegenerative disor-
ders.11,12 Microglia express a wide array of phagocytic receptors
that are involved in receptor-mediated phagocytosis in the CNS.13
Dysregulated expression of microglial phagocytic receptors has
been shown to result in impaired microglial phagocytosis.14 The cur-
rent study was undertaken to understand how morphine exposure
impairs microglial phagocytosis involving the astrocyte-microglial
crosstalk.
Extracellular vesicles (EVs) comprising microvesicles, exosomes, and
apoptotic bodies play important roles as cargo-carrying vesicles medi-
ating communication among diverse cells types and tissues, including
the CNS.15–18 Studies by others15 and us16 have demonstrated that
EVs released from astrocytes, the most abundant cell type in the
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CNS, can be conduits for delivering the cargo of macromolecules to
neighboring as well as distant cells, culminating in a wide spectrum
of functional changes in the recipient cells. Exploiting this cargo de-
livery function of EVs has been critical in understanding how EVs can
also be developed as vehicles for targeted delivery of therapeutic drugs
to tissues.19 For example, an exciting study by Zhuang et al.20 has
demonstrated that intranasal delivery of exosomes loaded with
curcumin can target the microglia, resulting in reduction of lipopoly-
saccharide (LPS)-induced neuroinflammation.
Long intergenic noncoding RNAs (lincRNAs) are regulatory RNA
molecules and play pivotal roles in the regulation of many cellular
processes.21,22 Our previous studies have demonstrated that the
transcription of lincRNA-Cox2 is regulated by the nuclear factor
kB (NF-kB) signaling pathway and is required for the transcription
of late primary inflammatory-response genes.23,24 In the current
study, we demonstrate that morphine-stimulated astrocyte-derived
EVs (morphine-ADEVs) can be taken up by microglial cells,
leading, in turn, to impaired microglial phagocytosis via the Toll-
like receptor 7 (TLR7)-NF-kB-lincRNA-Cox2 axis. Additionally, we
also demonstrate that intranasal delivery of lincRNA-Cox2 small
interfering RNA (siRNA) can restore microglial phagocytic activity
in morphine-administered mice.
RESULTS
Morphine Induces Release of EVs from Astrocytes
Astrocytes perform essential functions to sustain homeostasis within
the CNS, including proper maintenance of water and ion balance,
removal of extracellular glutamate, and release of neurotrophic fac-
tors.25 In addition, astrocytes have developed multiple avenues of
intercellular communication and transfer of various factors including
RNA. It is well known that astrocytes can communicate via
direct cell-cell interactions and gap junctions; however, over the last
few years, it is increasingly being appreciated that astrocytes also
communicate with many, if not all, cells within the CNS, through
the release and uptake of EVs. Herein we first sought to isolate and
characterize EVs from conditioned media of human astrocyte A172
cells, as well as mouse and human primary astrocytes, using a differ-
ential ultracentrifugation procedure (Figure 1A).16,26 Purified EVs
were characterized by western blot for signature exosomal markers,
as well as by transmission electron microscopy (TEM) and atomic
force microscopy (AFM). As shown in Figure 1, immunoblotting of
the EV lysates revealed the presence of exosomal markers TSG101,
CD63, and Alix. Additionally, immunoblotting using calnexin was
also done to demonstrate that isolated ADEVs were free of contami-
nation with cell debris (Figure 1B). Further characterization of EVs
using TEM and AFM demonstrated EVs ranging from 40 to
100 nm in diameter (Figures 1C and 1D). Given that astrocytes ex-
press high levels of mu opioid receptors and have been shown to
respond to morphine, we next sought to examine the effect of
morphine on the number and size of ADEVs using nanoparticle
tracking analysis (NTA). As shown in Figures 1E and 1F, exposure
of astrocytes to morphine (10 mM, 24 hr) resulted in significantly
increased numbers of released EVs compared with the control cells.
There was, however, no effect on the size distribution of EVs in the
presence of morphine.
EVs Are Taken up by Microglia and Reach the Endosomes
Because microglia are the primary phagocytic immune cells within
the CNS, we next asked whether ADEVs could be taken up by micro-
glia and, if so, could they reach the endosomes, the site for RNA-
sensing TLRs. For this, we cultured mouse primary microglia with
EVs isolated from mouse primary astrocytes that were transfected
with a plasmid encoding the exosomal marker TSG101 fused with
mCherry. As observed in Figure 2A, mouse primary microglia
cultured with RFP-tagged EVs (30 min) demonstrated a fine granular
fluorescent pattern within the cytoplasm, suggesting thereby that EVs
could reach and release their contents into the microglial cells. We
next sought to assess whether ADEVs taken up by microglia could
reach the endosomes; mouse primary microglia were exposed to
mouse primary astrocyte-derived RFP-tagged EVs for 30 min, fol-
lowed by harvesting of cells for localization of EVs at the endosomes.
Cells were immunostained for the endosomal marker EEA1 and also
assessed for the RFP-tagged ADEVs by confocal microscopy. As
shown in Figure 2B, microglia were able to take up mCherry-
TSG101 ADEVs and, furthermore, these ADEVs were found to
co-localize within the microglial endosomes.
Endosomal receptors TLR7 and TLR8 are known to bind AU- or GU-
rich single-stranded RNA ligands, leading to activation of the down-
stream NF-kB signaling pathway.27 For example, Forsbach et al.27
have identified 15 AU- or GU-containing 4-mers that function as
TLR7/8 RNA agonists. Interestingly, EV microRNAs (miRNAs) con-
taining the TLR7/8 binding motifs have also been shown to function
as TLR7/8 agonists.18,28,29 Based on our findings that ADEVs taken up
by the microglia could reach the endosomes, we next sought to inves-
tigate whether ADEV-miRNAs could also serve as TLR7/8 RNA ag-
onists. For this, we performed an TLR7/8 binding elements search
within the known mouse mature miRNA sequence database (miR-
Base,30 version 21). Moreover, the extracellular mouse miRNAs anno-
tation was also obtained from the EV miRNA databases, ExoCarta31
and EVpedia.32 We found that almost 1,079 out of 2,049 mouse miR-
NAs contained at least one AU- or GU-rich 4-mers, as reported by
Forsbach et al.,27 with 38 of them reported to be present in EVs (Fig-
ure 2C; Table S1). Based on these 38 reported EV-miRNAs, which are
potential TLR7/8 RNA agonists, we next conducted motif prediction
using MDS2,33 and three possible motifs were predicted (Figure 2D)
covering 66.0% to 79.0% of the 38 EV-miRNAs as potential TLR7/8
RNA agonist. Next, we sought to examine whether morphine-ADEVs
also contained the TLR7/8 motifs. For this, RNA was purified from
control- or morphine-ADEVs isolated from human primary astro-
cytes and subjected to RNA-sequencing (RNA-seq) analyses. As
shown in Figure 2E, 15 of the 4-mer containing miRNAs were signif-
icantly upregulated and, 9 of the 4-mer containing miRNAs were
downregulated in morphine-ADEVs compared with control-ADEVs.
Selective differentially expressed miRNAs identified from the RNA-
seq analysis were further validated using qPCR (Figure 2F). Interest-
ingly, the total reads from the RNA-seq data for miRNAs in
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morphine-ADEVs were significantly increased compared with that in
control-ADEVs, indicating thereby that morphine-ADEV-miRNAs
could serve as TLR7/8 RNA agonists in the recipient microglia.
Morphine-ADEV-Induced Nuclear Translocation of Endogenous
NF-kB p65 Involves Endosomal TLR7 Signaling in Microglia
Having determined that EVs can reach the endosomes and deliver AU-
and GU-rich miRNAs, which could activate TLR7/8, the next logical
step was to investigate the downstream signaling of the TLR7/8
pathway, in particular, nuclear translocation of NF-kB and microglial
activation.34 To this end, we thus sought to examine whether
morphine-induced EVs released from astrocytes could activate
NF-kB in microglia. Mouse primary microglia were stimulated with
either control- or morphine-ADEVs isolated from mouse primary as-
trocytes for 30 min followed by immunocytochemistry for transloca-
tion of p65. As shown in Figure 3A, microglial cells stimulated with
morphine-ADEVs demonstrated significantly increased translocation
of NF-kB p65 from the cytoplasm into the nucleus compared with
cells exposed to control-ADEVs (Figure 3A). Intriguingly, and as ex-
pected, morphine-ADEVs failed to promote nuclear translocation of
p65 in TLR7 knockout (KO) microglial cells (Figure 3B). These find-
ings were further confirmed by immunoblotting. To further investigate
whether morphine-ADEV-mediated translocation of NF-kB could be
attributed to the miRNA cargo in the EVs, we transfected mouse pri-
mary astrocytes with either control or Dicer-siRNA for 24 hr, and sub-
sequently exposed them tomorphine for an additional 24 hr. EVs were
then isolated from the conditioned media and exposed to either wild-
type (WT) or TLR7 KOmouse microglial cells for 30 min, followed by
detection of nuclear translocation of the NF-kB p65 subunit by western
blotting and fluorescent immunostaining. As shown in Figures 3C–3E
Figure 1. Characterization of EVs Isolated from Astrocyte Culture
(A) Schematic representation of the major steps involved in the EV isolation from astrocyte culture. (B) Western blot characterization of astrocyte EVs. Protein isolated from
astrocyte EVs was separated on SDS-PAGE and electroblotted onto nitrocellulose membrane. Blots were probed with exosome marker antibody against TSG101, CD63,
and Alix. Calnexin was used as a control for cell debris contamination. (C) Representative electron micrograph of EVs isolated from A172 cells. Scale bar, 200 nm. (D) AFM
image of EVs isolated from mouse primary astrocyte culture supernatants. (E) Size and particle distribution plots of isolated EVs from cell culture by NanoSight Tracking
Analysis (NTA). The plot shows a peak size around 80 nm for the isolated EVs. (F) Number of EVs isolated from control and morphine-exposed human primary astrocytes. All
experiments were done at least three independent times. Data are shown as mean ± SEM. *p < 0.05 versus control.
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and Figure S1, EVs isolated from morphine-stimulated, Dicer KO
astrocytes failed to induce nuclear translocation of NF-kB p65 in
WT microglia. These data thus underpin the pivotal role of miRNA
cargo of the morphine-ADEVs in activating the TLR7-NF-kB
signaling pathway.
Morphine-ADEVs Induce lincRNA-Cox2 Expression in Microglia
via the TLR7/NF-kB Signaling Pathway
Studies from others35 and us24 have demonstrated that lincRNA-
Cox2 is an early-primary gene regulated by NF-kB signaling in
myeloid cells such as macrophages and microglia. Herein we sought
Figure 2. EVs Are Internalized by Microglial Cells and Localize to Late Endosomes
(A and B) Mouse primary microglial cells were incubated with EVs purified from pEF6.mCherry-TSG101-transfected mouse primary astrocytes for 20 min. Paraformaldehyde
fixedmicroglial cells were permeabilized and stained for (A) Iba1 or (B) EEA1, followed by FITC-conjugated secondary antibody and visualized by fluorescencemicroscopy. Scale
bars, 10 mm. (C) Barplot showing the number of miRNAs (light blue) and EV-miRNAs (red) that contain various numbers of AU- or GU-rich motifs. (D) Sequence logos AU- and
GU-rich motifs of EVmiRNAs. (E) Heatmap of expression profile of AU- and GU-rich miRNAs in EVs from control and morphine-stimulated human primary astrocytes. (F) qPCR
validation of representative differentially expressed miRNAs identified from the RNA-seq. All experiments were done at least three independent times. *p < 0.05 versus control.
www.moleculartherapy.org
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to examine whether morphine-ADEVs that are taken up by micro-
glial cells could, via the TLR7-NF-kB axis, lead to upregulation of
lincRNA-Cox2 expression. To address this, we pretreated mouse pri-
mary microglia with either SC-514 (NF-kB inhibitor) or chloroquine
(TLR7 inhibitor) followed by stimulation with either control- or
morphine-ADEVs isolated from mouse primary astrocytes for 4 hr.
Expression of lincRNA-Cox2 was analyzed by real-time PCR. As pre-
sented in Figure 4A, expression of lincRNA-Cox2 was significantly
increased in microglial cells stimulated with morphine-ADEVs
compared with its expression in microglia exposed to control-
ADEVs. In microglia pretreated with either SC-514 or chloroquine,
morphine-ADEVs failed to induce expression of lincRNA-Cox2 (Fig-
ure 4A). To further validate our results, we also assessed lincRNA-
Cox2 expression in mouse primary microglia isolated from either
C57BL/6N WT or TLR7 KO mice that were stimulated with either
control- or morphine-ADEVs from mouse primary astrocytes. As
shown in Figure 4B, exposure of WT microglia to morphine-ADEVs
resulted in an upregulation of lincRNA-Cox2 expression, and in
contrast and as expected, morphine-ADEVs failed to upregulate
lincRNA-Cox2 expression in TLR7 KO microglial cells. Next, to
determine the site of action of lincRNA-Cox2, we performed RNA
fluorescent in situ hybridization (FISH) for lincRNA-Cox2 in micro-
glia. As shown in Figure 4C, FISH analysis revealed nuclear, perinu-
clear, as well as cytoplasmic expression of lincRNA-Cox2 in micro-
glial cells. Further validation of these findings was done by
assessing the expression of lincRNA-Cox2 in subcellular fractions
of microglia by real-time PCR. As shown in Figure 4D, lincRNA-
Cox2 expression was predominantly localized to the nucleus in the
microglia (Figure 4D), and as expected, GAPDHmRNAwas localized
to the cytosol, and U1 small nuclear RNA (snRNA) was confined to
the nucleus. Consistent with previous studies,24 these results indicate
that lincRNA-Cox2 could serve as a pivotal mediator regulating the
expression of other genes at the level of transcription in microglia.
Morphine-ADEVs Inhibited Microglial Phagocytosis
To determine the functional effects of induced lincRNA-Cox2 expres-
sion in microglia, we first designed lincRNA-Cox2 siRNAs, and the
knockdown efficiency of our siRNAs was evaluated by real-time
PCR in siRNA-transfected BV-2 cells. As shown in Figure 5A, both
lincRNA-Cox2 siRNAs significantly downregulated the expression
of lincRNA-Cox2 in microglia. We next performed microarray anal-
ysis to compare the gene expression profiles in both control and
lincRNA-Cox2 knockdown BV-2 microglia. We have previously re-
ported that lincRNA-Cox2 is a coregulator of transcription factor(s)
controlling inflammatory responses in microglia and macrophages.24
The interrelationship between lincRNA-Cox2 and phagocytosis
Figure 3. EVs Released from Morphine-Exposed Astrocytes Induce Nuclear Translocation of NF-kB
(A and B) Wild-type (A) and TLR7 KO (B) mouse primary microglial cells were treated with EVs (2 mg of EVs per 2  105 cells) isolated from morphine-exposed astrocytes for
30 min. The subcellular localization of endogenous p65 was visualized by indirect immunofluorescence using anti-p65 antibodies (green). Nuclear DNA was revealed by DAPI
staining. Scale bars, 50 mm. (C and D) Primary mouse astrocytes were transfected with either control or Dicer-siRNA for 24 hr, followed by morphine exposure for 24 hr. Wild-
type (C) and TLR7 KO (D) mouse microglial cells were exposed to EVs (30 min) isolated from astrocyte conditioned media followed by detection of NF-kB p65 in the nuclear
fraction bywestern blot. (E) All experimentswere done at least three independent times. Band intensities of the cytoplasmic and nuclear extractswere quantified andnormalized
against b-actin and histone H3, respectively, and compared with untreated cells. All data are presented as mean ± SD. *p < 0.05 versus control using Student’s t test.
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in microglia, however, remains largely unknown. Based on the micro-
array analysis, in lincRNA-Cox2 knocked-down microglia, we identi-
fied several phagocytic genes, including Lrp1, Syk, and Pld2, that were
negatively regulated by lincRNA-Cox2 (Figure 5B). These findings
were also validated in mouse primary microglia. As shown in Fig-
ure 5C, in mouse primary microglia exposed to morphine-ADEVs
there was decreased expression of Lrp1, Pld2, and Syk compared
with cells exposed to control-ADEVs. Interestingly, knocking down
lincRNA-Cox2 significantly increased the expression of Lrp1, Pld2,
and Syk in microglia exposed to either control- or morphine-ADEVs
compared with microglia transfected with scrambled siRNA. To eval-
uate the effects of induced lincRNA-Cox2 on phagocytosis, we
transfected BV-2 microglial cells with either control or lincRNA-
Cox2-specific siRNA for 24 hr, followed by stimulation with either
control- or morphine-ADEVs for another 24 hr. The cells were
then allowed to internalize fluorescently labeled IgG-opsonized latex
beads for 2 hr followed by extensive washes and fixing of cells. Fixed
cells were then stained with DAPI and analyzed for phagocytic uptake
of the beads using fluorescence microscopy (Figure S2A) and a fluo-
rometric plate reader (Figure S2B). As shown in Figures S2A and S2B,
microglia treated with morphine-ADEVs displayed significantly
reduced internalization (R40% inhibition) of IgG-opsonized latex
beads compared with cells treated with control-ADEVs. Intriguingly,
knockdown of lincRNA-Cox2 promoted internalization of IgG-
opsonized latex beads in microglia following interaction with
either control- or morphine-ADEVs compared with scrambled
Figure 4. Morphine Astrocyte EV-Mediated Induction
of lincRNA-Cox2 Involves TLR7 and NF-kB
(A) Mouse primary microglial cells were pre-treated with
either TLR7 inhibitor (chloroquine 25 mM) or NF-kB inhibitor
(SC-514, 5 mM) for 1 hr, followed by exposure of cells for
4 hr to EVs (2 mg of EVs per 2  105 cells) isolated from
astrocyte conditioned media. Total RNA isolated from cells
was analyzed by real-time PCR for expression of lincRNA-
Cox2. (B) Mouse primary microglial cells were isolated from
wild-type and TLR7 KO pups, and exposed to EVs isolated
from morphine-stimulated astrocyte conditioned media for
4 hr. Total RNA from cells was analyzed by real-time PCR
for expression of lincRNA-Cox2. (C) Representative
confocal images of ISH assay using a probe specific for
lincRNA-Cox2 (red) combined with DAPI staining (blue) and
immunostaining for GAPDH (green) in mouse primary
microglia. Scale bar, 10 mm. (D) Subcellular fractionation
followed by qPCR for lincRNA-Cox2, U1 snRNA, and
GAPDH mRNA. All values are shown as the mean ± SEM.
*p < 0.05 versus control; #p < 0.05 versus treatment.
siRNA-transfected microglia (Figures S2A and
S2B). Next, we sought to validate the role of
morphine-ADEVs on microglial phagocytosis.
For this, mouse primary microglial cells were
transfected with either control- or lincRNA-
Cox2 siRNA for 24 hr followed by exposure of
cells to PKH26-labeled ADEVs (isolated from
mouse primary astrocytes) for an additional 24 hr and subsequent in-
cubation with fluorescent beads for 2 hr. As shown in Figure 2C, there
was decreased internalization of the beads (green) in morphine-
ADEV (red)-stimulated microglia compared with cells stimulated
with control-ADEVs (red). In microglial cells transfected with
lincRNA-Cox2 siRNA, however, there was increased internalization
of beads (green) in morphine-ADEV (red)-stimulated microglia
compared with cells transfected with control- siRNA and exposed
to morphine-ADEVs (red). These findings thus underpinned the
roles of morphine-ADEVs and lincRNA-Cox2 in microglial phagocy-
tosis. We next sought to examine whether the TLR7-NF-kB signaling
pathway was involved in phagocytosis. As presented in Figures 5D
and 5E, in the presence of inhibitors of either TLR7 or NF-kB,
morphine-ADEVs failed to abrogate microglial phagocytosis. These
findings were further confirmed in TLR7 KO microglia. As shown
in Figure 5F, morphine-ADEVs failed to inhibit phagocytosis in
TLR7 KO microglia. Together, these findings demonstrated that
morphine-ADEVs could be taken up by microglia, leading to activa-
tion of the TLR7-NF-kB signaling axis. This activation pathway, in
turn, resulted in upregulation of lincRNA-Cox2 expression, culmi-
nating in impaired microglial phagocytosis.
Knockdown of lincRNA-Cox2 Restored Morphine-Impaired
Phagocytic Activity In Vivo
Having determined that knockdown of lincRNA-Cox2 in microglia
was able to restore ADEV-mediated morphine-induced phagocytic
www.moleculartherapy.org
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impairment, we next sought to investigate whether knockdown of
lincRNA-Cox2 could also restore microglial phagocytic activity in
morphine-administrated mice. Targeting therapeutic drugs to the
CNS is a major challenge in the field owing to the tight blood-brain
barrier. Intranasal administration is a non-invasive route for drug
delivery, which is widely used for the treatment of rhinitis and nasal
polyposis.36,37 In recent times, EVs have not only been recognized
for their role as communication vesicles delivering cargo to neigh-
boring or distant cells, but have also been implicated as conduits
for efficient delivery of RNA drugs into the brain.20,38 Before pro-
ceeding to test the efficacy of siRNA-loaded EVs in our system, it
was first essential to assess the biodistribution of intranasally admin-
istered EVs. For this, WT mice were administered EVs labeled with
the PKH26-dye intranasally and 4 and 24 hr later, animals were
transcardially perfused with ice-cold PBS, followed by tissue harvest-
ing and monitoring for delivery efficacy and biodistribution using
the in vivo imaging system (IVIS). As shown in Figure 6A, labeled
EVs were primarily localized in the lungs, brain, gut, liver, and heart
following 4 hr of EV administration. Interestingly, in 24-hr post-EV
administration mice, labeled EVs were found in the brain and heart,
but were absent in the lungs and the gut. Next, we sought to examine
the uptake of labeled EVs by microglia in sections of striatum using
immunohistochemistry for PKH26+-labeled Iba1+ cells. As shown in
Figure 6B, there was a significant and specific uptake of labeled EVs
by the microglia. The next step was to assess the efficacy of the
siRNA-loaded ADEVs in morphine-administered mice. For this,
WT mice were given intraperitoneal injections of either saline or
morphine (10 mg/kg) twice a day for 5 consecutive days. Simulta-
neously, we also initiated intranasal delivery of ADEVs (20 mg
each time) loaded with either control or lincRNA-Cox2 siRNA to
Figure 5. Knockdown of lincRNA-Cox2 Restores EV-Mediated Impairment of Microglial Phagocytosis
(A) Real-time PCR for lincRNA-Cox2 in microglia transfected with lincRNA-Cox2 siRNA. (B) Heatmap of differentially expressed phagocytosis-associated genes in lincRNA-
Cox2 knockdown BV-2 cells compared with control cells. (C) Mouse primary microglial cells were transfected with lincRNA-Cox2 siRNA for 24 hr, followed by exposure of
cells to astrocyte EVs for 4 hr, and subsequently assessed for the expression of Lrp, Pld2, and Syk by qPCR. (D and E) Mouse primary microglial cells were pre-treated with
TLR7 inhibitor (chloroquine 25 mM) or NF-kB inhibitor (SC-514, 5 mM) for 1 hr, followed by exposure of cells to astrocyte EVs and subsequent exposure to fluorescent beads
for 2 hr. Phagocytosis was measured using (D) fluorescence microscopy (scale bar, 20 mm; high-magnification images are shown in the bottom right corners) and (E)
fluorometric plate reader. (F) TLR7 KO microglial cells were exposed to astrocyte-derived EVs and assessed for phagocytosis as described above. All data are presented as
mean ± SD. *p < 0.05 versus control; #p < 0.05 versus treatment using Student’s t test.
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the two groups of mice 1 hr prior to morphine or saline injections.
One hour after the last injection on day 5, mice were sacrificed fol-
lowed by microglial isolation and assessment of lincRNA-Cox2
expression by real-time PCR. As shown in Figure 6C, the expression
of lincRNA-Cox2 was significantly upregulated in microglia isolated
from morphine-administrated mice compared with the saline-in-
jected controls. Furthermore, intranasal delivery of lincRNA-Cox2
siRNA-loaded ADEVs resulted in a significant knockdown of
lincRNA-Cox2 in microglia isolated from morphine-administered
mice. The next step was to perform phagocytosis assay on the brain
slices from the two groups of mice that were intranasally delivered
loaded EVs. As shown in Figures 6D and 6E, there were fewer
fluorescent beads phagocytosed in morphine-administrated micro-
glia compared with saline-injected controls, suggesting thereby
that morphine administration impaired microglial phagocytosis
in the adult brain (Figures 6D and 6E). Intriguingly, intranasal deliv-
ery of lincRNA-Cox2 siRNA-loaded EVs restored microglial
phagocytic activity in morphine-administrated mice compared
with the morphine-administered mice that were treated with control
siRNA-loaded EVs.
DISCUSSION
EVs play an important role in cell-cell communication among
diverse cells types and tissues, including the CNS. The primary func-
tion of these vesicles is the delivery of their cargo comprising cellular
miRNAs, proteins, and DNA to neighboring as well as distant cells,
resulting in impairment of cellular functions.16,39–41 For example, in
our previous study, we have shown that both morphine and HIV
Trans-Activator of Transcription (Tat) protein upregulated miR-
29b in ADEVs, which, in turn, resulted in neuronal death. Along
these lines, studies by Yelamanchili et al.18 also demonstrated that
HIV infection resulting in significant upregulation of miR-21 in
blood macrophage-derived EVs in turn directly activated the
TLR7-dependent downstream necroptosis pathway. Our miRNA-
seq profiling of morphine-ADEVs demonstrating enrichment of
miRNAs with an AU- or GU-rich motif critical for direct activation
of TLR7 is in keeping with published reports on the role of EV
miRNAs in this process.28,29 The process by which EV-miRNA-
mediated activation of TLR7 leads to upregulation of lincRNAs
that regulate cellular function(s), however, remains less understood.
In the current study, we demonstrate that exposure of mouse
Figure 6. Knockdown of lincRNA-Cox2 Ameliorates Morphine-Mediated Impairment of Phagocytic Activity of Microglia In Vivo
(A) PKH26-labeled EVs (20 mg) were intranasally delivered toWTmice (n = 3). Mice were sacrificed 4 and 24 hr posttreatment, and the harvested organs were imaged using a
Xenogen IVIS 200 imager. A scale of the radiance efficiency is presented on the right. (B) Immunostaining of the brain sections of mice administered PKH26-labeled EVs for
the microglial marker Iba1 (green). Representative micrographs are shown (original magnification 20). Scale bar, 100 mm. (C) Real-time PCR for lincRNA-Cox2 in the
CD11b+/CD45+ dim population of microglia sorted from the brains of various groups of mice. (D) Representative micrograph of brain slices (from 8-week-old mice) incubated
with fluorescent beads (green). Scale bar, 20 mm. (E) Quantification of the number of Iba1-positive (red) microglia (with phagocytosed beads) normalized to the total number of
Iba1-positive cells. n = 20 fields of view from three mice. All data are presented as mean ± SD; *p < 0.05 versus saline/si-control group; #p < 0.05 versus morphine/si-control
group using Student’s t test.
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microglial cells to morphine-ADEVs resulted in impaired phago-
cytic function involving the TLR7-NF-kB-lincRNA-Cox2 axis. To
determine whether morphine-ADEVs increased lincRNA-Cox2
in vivo, mice were intranasally administered ADEVs isolated from
either control- or morphine-stimulated mouse primary astrocytes,
and brain sections were assessed for the expression of lincRNA-
Cox2 using double in situ hybridization (ISH) and immunostaining
for Iba1. Additionally, microglia were also isolated ex vivo by flow
cytometry from the mice brains and assessed for the expression of
lincRNA-Cox2 by qPCR, and as shown in Figures S3A and S3B,
intranasal delivery of morphine-ADEVs increased the expression
of lincRNA-Cox2 in microglia. Future studies using human astro-
cytes and microglia are warranted to provide additional insights in
the underlying mechanism(s). Recently, Abud et al.42 have demon-
strated that human microglial-like cells (iMGLs) can be generated
from iPSCs (induced pluripotent stem cells) and can be used for
investigation of microglial functions in various CNS disorders,
including substance use disorder. Another advantage of such a
model system is that it enables investigating the effect of ADEVs
on microglia from the same donor. It must be noted that the miRNA
cargo in EVs can also affect the functioning of the recipient cells
via miRNA-mRNA interactions. Future IPA (Ingenuity Pathway
Analysis) bioinformatic analysis will be essential to understand
the complex regulatory networks regulated by the dysregulated
miRNAs in morphine-ADEVs. Future efforts will be aimed at
downregulating the dysregulated miRs in the microarray screen,
which, in turn, could further help establish a link between the EV-
TLR7/8 and linc-RNA-Cox2 pathway in the context of microglial
phagocytosis.
Phagocytes play a vital role in the maintenance of tissue homeostasis
by promoting rapid clearance of apoptotic cells, pathogens, and other
insults, leading, in turn, to the elimination of immunogens and pre-
vention or resolution of inflammation.43 Elegant studies by Ninkovic
et al.44 have previously demonstrated impairment of bacterial phago-
cytosis by macrophages following morphine exposure, and that this
effect was mediated by opioid receptors and the subsequent down-
stream inhibition of actin polymerization and pathogen internaliza-
tion. These findings thus suggested that the inhibitory effects of
morphine on macrophage phagocytosis and pathogen clearance
could lead to exacerbation of disease pathogenesis and recovery
from a wide range of diseases and injuries. Controversial in vitro
studies demonstrating morphine-mediated enhancement of Crypto-
coccus neoformans and Mycobacterium tuberculosis phagocytosis by
human microglia, involving the complement or G protein-coupled
opiate receptors, respectively, have also been reported.3,4 It has been
shown that chronic morphine administration can mediate both the
activation and repression of phagocytosis-related genes in the stria-
tum of C57BL/6N mice45 (data obtained from NCBI-GEO database
accession code GEO: GSE7762, analyzed with GEO2R tool, and pre-
sented in Table S2). In the current study, we identified 20 phagocy-
tosis-related genes regulated by lincRNA-Cox2, and out of these, 15
are negatively regulated. We also demonstrate yet another novel func-
tion of lincRNA-Cox2, that of negatively regulating microglial phago-
cytosis using both in vitro and in vivo model systems. Our previous
studies shed light on the role of lincRNA-Cox2 as a critical mediator
for the development of inflammatory responses in both microglia and
macrophages. The current finding of its inhibitory role in microglial
phagocytosis has ramifications for therapeutics. Knockdown of
lincRNA-Cox2 could thus be considered as a therapeutic strategy
aimed at restoring bothmicroglial phagocytic function andmitigating
neuroinflammation associated with opiate abuse.
Gene therapy is becoming a promising tool for the treatment of human
diseases that cannot be cured by conventional therapies. In fact, RNA-
based approaches such as siRNA, antisense RNA, and miRNAs—
potent sequence-selective inhibitors of transcription—are rapidly
being developed as therapeutics. Elegant studies have demonstrated
the use of EVs to successfully deliver siRNAs to specific cell
types in vivo in rodents.46 Intranasal administration of exosomes is
considered a noninvasive method for rapid delivery of exosome-
encapsulated drug(s) to the brain with selective uptake by microglial
cells.20,36,47,48 Manipulating EVs with miRNAs, anti-miRNAs, or
siRNAs in vivo could thus be envisioned as an efficient means to
deliver these molecules to the target cells or organs. Our data clearly
demonstrate that exposure of astrocytes to morphine leads to
increased release of ADEVs, which upon uptake by themicroglia result
in upregulated expression of a NF-kB-regulated gene, lincRNA-Cox2,
in the recipient cells, ultimately leading to impaired microglial phago-
cytosis. Furthermore, our in vivo study, for the first time, also demon-
strates that intranasal delivery of lincRNA-Cox2 siRNA restored
microglial phagocytic activity of morphine-administered mice.
In conclusion, our findings suggest that exposure of microglial cells to
morphine-ADEVs results in impaired phagocytic function via the
TLR7-NF-kB-lincRNA-Cox2 axis. We also demonstrate that knock-
down of lincRNA-Cox2 restores morphine-impaired phagocytic
activity in microglia in vivo. These findings have ramifications for
the development of EV-loaded RNA drug target(s) as therapeutics
for a multitude of neurodegenerative disorders including those asso-
ciated with opiate abuse.
MATERIALS AND METHODS
Animals
All animal procedures were performed in strict accordance with the
protocols approved by the Institutional Animal Care and Use Com-
mittee at the University of Nebraska Medical Center (UNMC) and
the NIH. C57BL/6N WT mice were purchased from Charles River
Laboratories (Wilmington, MA, USA) and housed under conditions
of constant temperature and humidity on a 12-hr light and 12-hr dark
cycle, with lights on at 7:00 a.m. Food and water were available ad
libitum. Tlr7/ mice were purchased from Jackson Laboratories
(Bar Harbor, ME, USA) and bred in the UNMC animal facility. Preg-
nant WT mice were purchased from Charles River Laboratories.
Intranasal Delivery of EVs in Mice
For intranasal administration of EVs, we anesthetized C57BL/6N
mice and placed them in a supine position in an anesthesia chamber.
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EVs (20 mg/100 mL) in saline were administered intranasally as drops
with a small pipette every 2 min into alternating sides of the nasal
cavity for a total of 10 min. To determine tissue distribution of EVs
in vivo, we harvested various tissues and monitored for efficiency of
delivery and biodistribution using a Xenogen IVIS 200 imager.
Cell Culture and Cell Lines
The human astrocytic cell line A172 (no. CRL-1620; American Type
Culture Collection [ATCC]) was cultured as described previously49
and maintained in DMEMwith high glucose containing 10% heat-in-
activated fetal bovine serum (FBS), 2 mM glutamine, penicillin
(100 U/mL), streptomycin (100 mg/mL), essential amino acids, and
vitamins. In this study, A172 cells were used within 30 passages. Hu-
man primary astrocytes were obtained from ScienCell Research
Laboratories (Carlsbad, CA, USA) and were cultured in DMEM/
F12 medium (Invitrogen Life Technologies, Carlsbad, CA, USA) con-
taining 10% heat-inactivated FBS, 2 mM glutamine, sodium bicar-
bonate, gentamicin, non-essential amino acids, and vitamins.
Mouse primary astrocytes were prepared from whole brains of
post-natal (1- to 3-day-old) C57BL/6N mice and plated on poly-D-
lysine pre-coated cell culture flasks containing DMEM (10% FBS,
100 U/mL penicillin, and 100 mg/mL streptomycin). The cells were
grown in a humidified atmosphere of 5% CO2/95% air at 37C.
When the astrocytes reached confluence, they were passaged by tryp-
sinization and plated at a density of 106 cells/well on 24-well culture
plates in a final volume of 1 mL of DMEM and grown in a humidified
atmosphere of 5% CO2/95% air at 37C. Two days later, the astrocytes
were used for experimentation. Immunocytochemical analyses
demonstrated that the cultures were comprised of >95% glial fibrillary
acidic protein (GFAP)-positive astrocytes.
Mouse primary microglia cells were obtained from 1- to 3-day-old
C57BL/6N or TLR7/ newborn pups, as described previously.50,51
After digestion and dissociation of the dissected brain cortices in
Hank’s buffered salt solution supplemented with trypsin (0.25%),
mixed glial cultures were prepared by resuspending the cell suspen-
sion in DMEM supplemented with 10% heat-inactivated FBS,
100 U/mL penicillin, and 0.1 mg/mL streptomycin. Cells were plated
at 20 106 cells/flask density onto 75-cm2 cell culture flasks. The cell
mediumwas replaced every 5 days, and after the first medium change,
macrophage colony-stimulating factor (M-CSF; 0.25 ng/mL; Pepro-
Tech, Rocky Hill, NJ, USA) was added to the flasks to promote micro-
glial proliferation.
The BV-2 microglial cell line was generously provided by Dr. Sanjay
Maggirwar (University of Rochester Medical Center, Rochester, NY,
USA). Cells were grown and routinely maintained at 37C and 5%
CO2 in DMEM supplemented with 10% heat-inactivated FBS, 100
IU/mL penicillin, and 100 mg/mL streptomycin.
EV Isolation
EVs were prepared from the supernatant of primary astrocytes and
A172 cells by differential centrifugations as previously described.16,26
In brief, conditioned media were harvested, centrifuged at 1,000  g
for 10 min to eliminate cells, and again spun at 10,000 g for 30 min,
followed by filtration through a 0.22-mm filter to remove cell debris.
EVs were pelleted by ultracentrifugation (Beckman Ti70 rotor; Beck-
man Coulter, Brea, CA, USA) at 100,000  g for 70 min. EVs were
assessed for their protein content using a BCA Protein Assay Kit
(Pierce, Rockford, IL, USA). TSG101 and CD63 were detected by
western blot as exosome markers. EVs were further quantified by
NTA using a NanoSight (model NS300), as previously reported.26
Cell and EV Transfection
Plasmid and siRNA transfections were performed using Lipofect-
amine 2000 (catalog no. 11668027; Life Technologies) according to
the manufacturer’s instructions. In brief, cells were transfected with
plasmid (500 ng) or targeted siRNA (20 pM) mixed with 2 mL of Lip-
ofectamine 2000 diluted in 100 mL of Opti-MEM (catalog no.
31985062; Life Technologies). The resulting siRNA-lipid complexes
were added to the cells, incubated for 6 hr, and the medium changed
into fresh DMEM. Next, the medium was changed to 10% FBS-con-
taining medium for 20-hr incubation. The transfected cells were then
ready for use in experiments. pEF6.mCherry-TSG101 was a gift from
Quan Lu (Addgene plasmid 38318).52 CD63-pEGFP was a gift from
Paul Luzio (Addgene plasmid 62964). Sequences of mouse Dicer1
siRNA oligonucleotides used in this study were: mouse Dicer1-siS1,
50-GrUrGrUrCrArUrCrUrUrGrCrGrArUrUrCrUrArUrUr-30; mouse
Dicer1-si AS1, 50-UrArGrArArUrCrGrCrArArGrArUrGrArCrArCr
UrUr-30; mouse Dicer1-siS1, 50-CrCrArArCrUrArCrCrUrCrArUrAr
UrCrCrCrArUrUr-30; mouse Dicer1-si AS2, 50-UrGrGrGrArUrArU
rGrArGrGrUrArGrUrUrGrGrUrUr-30.
EVs were transfected with siRNA using Exo-Fect Exosome Transfec-
tion Reagent (SBI; System Biosciences) according to themanufacturer’s
instructions. Sequences of mouse lincRNA-Cox2 siRNA oligonucleo-
tides used in this study were: Control-(si)S1, 50-rUrArArGrGrCrUr
ArUrGrArArGrArGrArUrArCrUrU-30; Control-(si)AS1, 50-rGrUrAr
UrCrUrCrUrUrCrArUrArGrCrCrUrUrArUrU-30; lincRNA-Cox2-
(si)S1, 50-rGrCrCrCrUrArArUrArArGrUrGrGrGrUrUrGrUrUrU-30;
lincRNA-Cox2-(si)AS1, 50-rArCrArArCrCrCrArCrUrUrArUrUrAr
GrGrGrCrUrU-30; lincRNA-Cox2-(si)S2, 50-rGrArGrArGrArGrAr
GrUrGrUrArCrUrUrArArArUrU-30; lincRNA-Cox2-(si)AS2, 50-rUrU
rUrArArGrUrArCrArCrUrCrUrCrUrCrUrCrUrU-30.
Western Blotting
Treated cells or EVs were lysed using the Mammalian Cell Lysis kit
(Sigma, St. Louis, MO, USA) and quantified using the micro BCA Pro-
tein Assay kit (Pierce, Rockford, IL, USA). Equal amounts of the cor-
responding proteins were electrophoresed in an SDS-polyacrylamide
gel (10%–12%) under reducing conditions followed by transfer to pol-
yvinylidene fluoride (PVDF) membranes. The blots were blocked with
5% non-fat dry milk in PBS. Western blots were then probed with an-
tibodies recognizing the CD63 antibody (1:1,000; ab216130; Abcam,
Cambridge, MA, USA), TSG101 (1:1,000; ab125011; Abcam, Cam-
bridge, MA, USA), NF-kB p65 (1:2,000; ab16502; Abcam, Cambridge,
MA, USA), histone H3 (1:1,000; catalog no. 9715S; Cell Signaling
www.moleculartherapy.org
Molecular Therapy: Nucleic Acids Vol. 13 December 2018 459
Technology, Danvers, MA, USA), and b-actin (1:4,000; A5316; Sigma,
St. Louis,MO, USA). The secondary antibodies were alkaline phospha-
tase-conjugated to goat anti-mouse/rabbit IgG (1:5,000). Signals were
detected by chemiluminescence and imaged on the FLA-5100 (Fuji-
film, Valhalla, NY, USA) digital image scanner; densitometry was per-
formed utilizing ImageJ software (NIH).53
Electron Microscopy
EV pellets were prepared for negative staining employing a slightly
modified procedure. Using wide-bore tips, 3 mL of EV pellet was
gently placed on 200-mesh Formvar-coated copper grids, allowed
to adsorb for 4–5 min, and processed for standard uranyl acetate
staining. In the last step, the grid was washed with three changes of
PBS and allowed to semi-dry at room temperature before observation
in TEM (Hitachi H7500 TEM; Hitachi, Tokyo, Japan).
Atomic Force Microscopy
The 1-(3-aminopropyl) silatrane (APS) mica functionalization pro-
cedure was used, in which freshly cleaved mica is treated with APS,
as previously described.54,55 Twenty microliters (8.3  109 EVs/mL)
of EV sample was deposited on APS mica for 20 min at room temper-
ature. Then 200 mL of the PBS buffer was added to the sample. The
sample was then subjected to AFM imaging. AFM imaging of EVs
was carried out using the Asylum Research MFP3D (Santa Barbara,
CA, USA) instrument. Imaging was performed in tapping mode at
room temperature. An MSNL probe with cantilever “E” (Bruker Cor-
poration) was employed for imaging. The nominal spring constant of
the MSNL “E” cantilevers was 0.1 N/m.
RNA Isolation and Sequencing
RNA was extracted from EVs, which were isolated from conditioned
media of human primary astrocytes of three donors. RNA samples
were then shipped on dry ice to LC Sciences (Houston, TX, USA)
for miRNA sequencing.
Real-Time PCR
For quantitative analysis of mRNA expression, comparative real-
time PCR was performed with the use of the SYBR Green PCR Mas-
ter Mix (Applied Biosystems). The sequences for the amplification
of lincRNA-Cox2 were: 50-AGTATGGGATAACCAGCTGAGGT-
30 (forward) and 50- GAATGCTGAGAGTGGGAGAAATAG-30
(reverse); the primer sequences for the amplification of U1 were
as follows: 50-CCATGATCACGAAGGTGGTTT-30 (forward); 50-
TATGCAGTCGAGTTTCCCGC-30 (reverse); and the primer se-
quences for the amplification of GAPDH were as follows: 50-
TGCACCACCAACTGCTTAGC-30 (forward); 50-ATGCCAGTGA
GCTTCCCGTT-30 (reverse). All reactions were run in triplicate.
Immunofluorescence
Cells grown on sterile coverslips were incubated with TSG101-
mCherry/CD63-EGFP-labeled EVs at 40% confluency. After 20–
30 min, cells were washed extensively with PBS and then fixed with
4% paraformaldehyde for 20 min at room temperature followed by
permeabilization with 0.3% Triton X-100 in PBS for 30min. The sam-
ples were incubated with a blocking buffer containing 10% goat serum
(NGS) in PBS for 2 hr at room temperature followed by addition of
rabbit anti-Iba1 antibody (1:1,000; Wako Laboratory Chemicals) or
rabbit anti-NF-kB p65 antibody (1:1,000; Abcam) or rabbit anti-
EEA1 antibody (1:200; Cell Signaling Technology) and incubated
overnight at 4C. Primary Abs were labeled with secondary anti-
rabbit Abs conjugated to the fluorescent probes Alexa Fluor 488 or
Alexa Fluor 594, and nuclei were labeled with DAPI.
Candidate TLR7/8 RNA Agonists miRNA Search and Motif
Prediction
To identify the potential mouse miRNAs that are capable of func-
tioning as the TLR7/8 RNA agonists, we performed an unbiased
search as follows: first, all known mouse mature miRNAs were
collected from miRBase30 (Version 21), and the mouse EV-miRNAs
were also obtained from two EV databases: ExoCarta31 and EVpe-
dia.32 Next, previously reported 15 AU- and GU-rich 4-mers from
the Forsbach et al.27 study were scanned for all known mouse
miRNAs. Finally, the EV-associated miRNAs that contained the re-
ported AU- and GU-rich 4-mers were considered as TLR7/8 RNA
agonists. Furthermore, sequence motif analysis was performed based
on the selected candidates using the tool MDS2.33
Cell Fractionation
Cells were fractionated using the NE-PER Nuclear and Cytoplasmic
Extraction Reagents kit to generate cytosolic and nuclear pools as
described by the manufacturer (Thermo Fisher).
lincRNA In Situ Hybridization
In situ hybridization for lincRNA was performed as described previ-
ously.56 Biotin-labeled antisense DNA probes (50-catggtttctcagaatg
tcc-30, 50-gcaacagtttcattcacagc-30, 50-aactgaagctttcactctcc-30, 50-gcaaat
cacagtcagttgct-30, 50-gactacttcctgctgattag-30, and 50-ctggataggactattt
ctcc-30) were designed using the online probe designer at http://
www.singlemoleculefish.com and synthesized by Integrated DNA
Technologies. The cells were fixed in 4% paraformaldehyde for
10 min, and washed and permeabilized with 0.25% Triton X-100 in
PBS for 15 min. Next, the slides were washed in PBS three times, fol-
lowed by incubation in hybridization buffer for 1 hr. Subsequently,
the DNA probes in hybridization buffer were added and incubated
in a humid chamber overnight at 55C. The next day, the slides
were washed in 2  saline-sodium citrate (SSC) three times for
2 min each at 42C and 0.2  SSC three times for 2 min each at
42C. Blocking was performed with blocking solution (3% NGS +
1% BSA in PBS) at room temperature for 2 hr and then incubated
with horseradish peroxidase (HRP)-labeled reagent (SA-HRP) and
cell-type marker at 4C overnight in a humidified chamber. On the
third day, slides were washed three times for 5 min each in TBS at
room temperature with agitation. Slides were incubated in streptavi-
din-HRP for 30 min at room temperature, then washed three
times for 5 min each in TBS buffer at room temperature. After that
the slides were incubated with the appropriate labeled secondary
antibody in 1% BSA, 1% NGS diluted in PBS at room temperature
for 1 hr. Then the slides were washed in 0.1% Tween 20 in TBS
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three times for 5 min each at room temperature. The slides were
then mounted using Prolong gold anti-fade reagent with DAPI
(Invitrogen).
Adult Microglia Isolation
Microglia were isolated from whole-brain homogenates by Percoll
gradient centrifugation according to previous reports50,51 with slight
modifications. In brief, the brains were homogenized in PBS (pH
7.4) by passing through a 70-mm nylon cell strainer. Resulting
homogenates were centrifuged at 600  g for 6 min. Supernatants
were removed and cell pellets were resuspended in 70% isotonic
Percoll (GE Healthcare, Uppsala, Sweden) at room temperature. A
discontinuous Percoll density gradient was layered as follows:
70%, 50%, 35%, and 0% isotonic Percoll. The gradient was centri-
fuged for 20 min at 2,000  g, and microglia were collected from
the interphase between the 70% and 50% Percoll layers. Cells were
washed and then resuspended in sterile PBS followed by flow cytom-
etry analysis by gating the myeloid cells for the CD11b+/CD45dim
population.
Phagocytosis Assay
The phagocytic activity of adult microglia of live brain slices was
analyzed as described previously.57,58 Brains from 8-week-old mice
were washed in carbogen-saturated (95% O2 and 5% CO2) artificial
cerebrospinal fluid (ACSF) containing (in mM): NaCl 126; KCl 2.5;
MgSO4 1.3; CaCl2 2.5; NaH2PO4 1.25; NaHCO3 26; and D-glucose
10 (pH 7.4; all from Sigma). Coronal slices (130 mm) were prepared
using a Vibratome (Microm, Walldorf, Germany) at 4C and allowed
to rest in ACSF buffer at room temperature for 1 hr before incubation
with fluorescein isothiocyanate (FITC)-labeled rabbit IgG-coated la-
tex beads 0.1 mm mean particle size (1:100; Cayman Chemical) for
60 min at 37C. The slices were washed and fixed with 4% parafor-
maldehyde. To visualize microglia, slices were permeabilized (0.25%
Triton X-100, 1% BSA, and 10% goat serum in PBS) and incubated
with anti-Iba1 (1:750; Wako), followed by goat anti-rabbit Alexa
488 (1:250; Invitrogen) and Hoechst 33258 (1:10,000; Sigma-
Aldrich). Fluorescent images were acquired at room temperature
on a Zeiss Observer Z1 microscope (Carl Zeiss, Germany); images
were processed using AxioVs 40 4.8.0.0 software (Carl Zeiss MicroI-
maging). Photographs were acquired using an AxioCamMRm digital
camera (Carl Zeiss, Germany).
To investigate the ability of microglia to internalize particles, micro-
glial cells (2  105 cells/mL) were plated on a 24-well plate and al-
lowed to adhere overnight, and then incubated with FITC-labeled
rabbit IgG-coated latex beads as described above, intensively washed,
and finally visualized at 20 magnification with a microscope.
Statistical Analysis
Statistical analysis was performed using Student’s t test or one-way
ANOVA followed by Holm-Sidak test (SigmaPlot 11.0). The appro-
priate test was clarified in the figure legends. Results were judged
statistically significant if p < 0.05 by ANOVA.
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